324 related articles for article (PubMed ID: 19200447)
21. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection.
Durbin AP; Elkins WR; Murphy BR
Vaccine; 2000 May; 18(22):2462-9. PubMed ID: 10738104
[TBL] [Abstract][Full Text] [Related]
22. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus.
Takimoto T; Hurwitz JL; Zhan X; Krishnamurthy S; Prouser C; Brown B; Coleclough C; Boyd K; Scroggs RA; Portner A; Slobod KS
Viral Immunol; 2005; 18(2):255-66. PubMed ID: 16035938
[TBL] [Abstract][Full Text] [Related]
23. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
24. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
25. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
26. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.
Jones BG; Sealy RE; Surman SL; Portner A; Russell CJ; Slobod KS; Dormitzer PR; DeVincenzo J; Hurwitz JL
Vaccine; 2014 May; 32(26):3264-73. PubMed ID: 24721531
[TBL] [Abstract][Full Text] [Related]
27. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
28. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection.
Marx A; Gary HE; Marston BJ; Erdman DD; Breiman RF; Török TJ; Plouffe JF; File TM; Anderson LJ
Clin Infect Dis; 1999 Jul; 29(1):134-40. PubMed ID: 10433576
[TBL] [Abstract][Full Text] [Related]
29. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.
Xue M; Wang R; Harder O; Chen P; Lu M; Cai H; Li A; Liang X; Jennings R; La Perle K; Niewiesk S; Peeples ME; Li J
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999025
[TBL] [Abstract][Full Text] [Related]
30. Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1.
Sealy R; Jones BG; Surman SL; Hurwitz JL
Vaccine; 2010 Sep; 28(41):6749-56. PubMed ID: 20682364
[TBL] [Abstract][Full Text] [Related]
31. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
Tang RS; MacPhail M; Schickli JH; Kaur J; Robinson CL; Lawlor HA; Guzzetta JM; Spaete RR; Haller AA
J Virol; 2004 Oct; 78(20):11198-207. PubMed ID: 15452239
[TBL] [Abstract][Full Text] [Related]
32. A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge.
Russell CJ; Jones BG; Sealy RE; Surman SL; Mason JN; Hayden RT; Tripp RA; Takimoto T; Hurwitz JL
Virology; 2017 Sep; 509():60-66. PubMed ID: 28605636
[TBL] [Abstract][Full Text] [Related]
33. Human parainfluenza virus type 1 immunization of infant mice protects from subsequent Sendai virus infection.
Sangster M; Smith FS; Coleclough C; Hurwitz JL
Virology; 1995 Sep; 212(1):13-9. PubMed ID: 7676623
[TBL] [Abstract][Full Text] [Related]
34. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
35. A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.
Kobayashi H; Iwatsuki-Horimoto K; Kiso M; Uraki R; Ichiko Y; Takimoto T; Kawaoka Y
Vaccine; 2013 Dec; 31(52):6239-46. PubMed ID: 24144478
[TBL] [Abstract][Full Text] [Related]
36. Antigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationship with Sendai virus revealed by using monoclonal antibodies.
Komada H; Kusagawa S; Orvell C; Tsurudome M; Nishio M; Bando H; Kawano M; Matsumura H; Norrby E; Ito Y
J Gen Virol; 1992 Apr; 73 ( Pt 4)():875-84. PubMed ID: 1378879
[TBL] [Abstract][Full Text] [Related]
37. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.
Adderson E; Branum K; Sealy RE; Jones BG; Surman SL; Penkert R; Freiden P; Slobod KS; Gaur AH; Hayden RT; Allison K; Howlett N; Utech J; Allay J; Knight J; Sleep S; Meagher MM; Russell CJ; Portner A; Hurwitz JL
Clin Vaccine Immunol; 2015 Mar; 22(3):298-303. PubMed ID: 25552633
[TBL] [Abstract][Full Text] [Related]
39. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.
Takimoto T; Hurwitz JL; Coleclough C; Prouser C; Krishnamurthy S; Zhan X; Boyd K; Scroggs RA; Brown B; Nagai Y; Portner A; Slobod KS
J Virol; 2004 Jun; 78(11):6043-7. PubMed ID: 15141002
[TBL] [Abstract][Full Text] [Related]
40. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
